Exelixis (EXEL) Competitors $36.94 -0.33 (-0.87%) As of 10:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EXEL vs. BIIB, INCY, UTHR, NBIX, BMRN, EXAS, HALO, RGEN, IONS, and MDGLShould you be buying Exelixis stock or one of its competitors? The main competitors of Exelixis include Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), Repligen (RGEN), Ionis Pharmaceuticals (IONS), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Exelixis vs. Its Competitors Biogen Incyte United Therapeutics Neurocrine Biosciences BioMarin Pharmaceutical Exact Sciences Halozyme Therapeutics Repligen Ionis Pharmaceuticals Madrigal Pharmaceuticals Biogen (NASDAQ:BIIB) and Exelixis (NASDAQ:EXEL) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment. Is BIIB or EXEL more profitable? Exelixis has a net margin of 27.01% compared to Biogen's net margin of 15.31%. Exelixis' return on equity of 27.47% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.31% 13.85% 8.32% Exelixis 27.01%27.47%20.88% Do analysts prefer BIIB or EXEL? Biogen currently has a consensus price target of $185.63, indicating a potential upside of 41.07%. Exelixis has a consensus price target of $44.44, indicating a potential upside of 20.33%. Given Biogen's higher probable upside, analysts clearly believe Biogen is more favorable than Exelixis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 21 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.34Exelixis 1 Sell rating(s) 8 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.55 Which has more volatility and risk, BIIB or EXEL? Biogen has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500. Does the media prefer BIIB or EXEL? In the previous week, Exelixis had 12 more articles in the media than Biogen. MarketBeat recorded 77 mentions for Exelixis and 65 mentions for Biogen. Biogen's average media sentiment score of 0.92 beat Exelixis' score of 0.64 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 32 Very Positive mention(s) 7 Positive mention(s) 16 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 23 Very Positive mention(s) 11 Positive mention(s) 15 Neutral mention(s) 11 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in BIIB or EXEL? 87.9% of Biogen shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 0.2% of Biogen shares are owned by insiders. Comparatively, 2.8% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has better earnings & valuation, BIIB or EXEL? Biogen has higher revenue and earnings than Exelixis. Biogen is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.68B1.99$1.63B$10.4612.58Exelixis$2.23B4.46$521.27M$2.0817.76 SummaryExelixis beats Biogen on 10 of the 16 factors compared between the two stocks. Get Exelixis News Delivered to You Automatically Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EXEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXEL vs. The Competition Export to ExcelMetricExelixisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.97B$3.02B$5.54B$9.48BDividend YieldN/A2.45%4.74%4.13%P/E Ratio17.8117.7728.9423.96Price / Sales4.46282.76412.94176.66Price / Cash19.3440.5624.4827.20Price / Book4.708.478.475.70Net Income$521.27M-$54.98M$3.25B$265.26M7 Day Performance-16.79%-3.41%-1.22%-2.41%1 Month Performance-19.55%15.62%7.82%6.73%1 Year Performance52.81%6.45%27.10%20.03% Exelixis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXELExelixis4.9461 of 5 stars$36.94-0.9%$44.44+20.3%+54.2%$9.97B$2.23B17.811,147Earnings ReportAnalyst DowngradeAnalyst RevisionBIIBBiogen4.8485 of 5 stars$128.86-0.3%$186.37+44.6%-35.8%$18.84B$9.68B12.697,605Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionINCYIncyte4.748 of 5 stars$76.89+9.6%$74.47-3.1%+17.2%$14.82B$4.41B239.302,617Analyst ForecastUTHRUnited Therapeutics4.9586 of 5 stars$298.91+0.3%$383.08+28.2%-10.2%$13.48B$2.88B11.921,305Trending NewsEarnings ReportShort Interest ↑Analyst RevisionGap UpNBIXNeurocrine Biosciences4.6874 of 5 stars$134.82+0.8%$163.87+21.5%-15.8%$13.34B$2.36B45.671,800Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionBMRNBioMarin Pharmaceutical4.9786 of 5 stars$58.42+0.5%$93.74+60.5%-31.0%$11.17B$2.85B21.653,040EXASExact Sciences4.4407 of 5 stars$47.30-1.5%$70.50+49.0%-16.7%$8.90B$2.76B-8.567,000Positive NewsUpcoming EarningsHALOHalozyme Therapeutics4.7694 of 5 stars$59.09+2.3%$62.70+6.1%+9.1%$7.28B$1.02B15.71390Positive NewsUpcoming EarningsRGENRepligen4.6941 of 5 stars$128.33+7.3%$169.92+32.4%-26.4%$7.21B$634.44M-285.141,778Earnings ReportAnalyst RevisionGap UpIONSIonis Pharmaceuticals4.5507 of 5 stars$41.38+0.5%$55.67+34.5%-12.4%$6.58B$705M-13.821,069Positive NewsEarnings ReportInsider TradeMDGLMadrigal Pharmaceuticals4.2795 of 5 stars$292.00-0.7%$420.63+44.0%+9.7%$6.48B$180.13M-16.1890Positive NewsUpcoming Earnings Related Companies and Tools Related Companies Biogen Alternatives Incyte Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives BioMarin Pharmaceutical Alternatives Exact Sciences Alternatives Halozyme Therapeutics Alternatives Repligen Alternatives Ionis Pharmaceuticals Alternatives Madrigal Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXEL) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exelixis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exelixis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EXEL Stock Alerts